Given that Maritoclax promote proteasomal degradation of MCL-1 (Doi et al. 2012; 2014), there was a reason to believe that combination with ABT-263 may overcome resistance and sensitise the NPC cell lines to ABT-263. This evidence concerns the gene MCL1 and nasopharyngeal carcinoma.